BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 20536653)

  • 1. Sarcoidosis during infliximab therapy for Crohn's disease.
    Takahashi H; Kaneta K; Honma M; Ishida-Yamamoto A; Ashida T; Kohgo Y; Ohsaki Y; Iizuka H
    J Dermatol; 2010 May; 37(5):471-4. PubMed ID: 20536653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.
    Cohen JD; Bournerias I; Buffard V; Paufler A; Chevalier X; Bagot M; Claudepierre P
    J Rheumatol; 2007 Feb; 34(2):380-5. PubMed ID: 17013997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
    Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
    J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
    Sorrentino D; Terrosu G; Vadalà S; Avellini C
    Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
    [No Abstract]   [Full Text] [Related]  

  • 6. [Development of cervical tuberculous lymphadenitis in a patient with Crohn's disease receiving infliximab despite of chemoprophylaxis with isoniazid].
    Ikeue T; Nakagawa A; Furuta K; Morita K; Sugita T; Nishiyama H
    Kekkaku; 2011 Nov; 86(11):879-82. PubMed ID: 22250467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.
    Massara A; Cavazzini L; La Corte R; Trotta F
    Semin Arthritis Rheum; 2010 Feb; 39(4):313-9. PubMed ID: 19147181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab.
    Fallon JC; Patchett S; Gulmann C; Murphy GM
    Clin Exp Dermatol; 2008 Jan; 33(1):43-5. PubMed ID: 17983451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn's disease.
    Vadikolias K; Kouklakis G; Heliopoulos I; Argyropoulou P; Papanas N; Tzilonidou M; Prassopoulos P; Piperidou H
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):159-62. PubMed ID: 17273002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The management of fistulizing oral Crohn's disease with infliximab.
    Staines KS; Green R; Felix DH
    J Oral Pathol Med; 2007 Aug; 36(7):444-6. PubMed ID: 17617840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease.
    Ahmad NM; Ahmad KM; Younus F
    J Infect; 2007 Jan; 54(1):e29-32. PubMed ID: 16678268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Listeria meningitis in a patient with Crohn's disease--a seldom, but clinically relevant adverse event of therapy with infliximab].
    Dederichs F; Pinciu F; Gerhard H; Eveld K; Stallmach A
    Z Gastroenterol; 2006 Aug; 44(8):657-60. PubMed ID: 16902896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept).
    Yazisiz V; Avci AB; Erbasan F; Yildirim B; Terzioğlu E
    Colorectal Dis; 2008 Nov; 10(9):953-4. PubMed ID: 18294265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cutaneous sarcoidosis in a patient with ulcerative colitis on infliximab.
    Fok KC; Ng WW; Henderson CJ; Connor SJ
    J Crohns Colitis; 2012 Jul; 6(6):708-12. PubMed ID: 22398084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis and psoriatic arthritis induced in a patient treated with infliximab for Crohn's disease.
    Tichy M; Tichy M; Kopova R; Sternbersky J; Ditrichova D
    J Dermatolog Treat; 2012 Jun; 23(3):208-11. PubMed ID: 21254868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
    J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflixmab as a possible treatment for the hemorrhagic type of Crohn's disease.
    Tsujikawa T; Nezu R; Andoh A; Saotome T; Araki Y; Ishizuka Y; Sasaki M; Koyama S; Fujiyama Y
    J Gastroenterol; 2004; 39(3):284-7. PubMed ID: 15065007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.